2023 Fall Clinical Virtual Grand Rounds
2023 Virtual Grand Rounds Session 17: December 13, 2023 - Managing Vitiligo and Other Pigmentary Disorders; What You Need to Know NOW About Alopecia Areata
About
Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:
Wednesday, December 13, 2023
8 PM ET / 5 PM PT
Managing Vitiligo and Other Pigmentary Disorders
What You Need to Know Now About Alopecia Areata
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
December 14, 2023
December 14, 2024
Learning Objectives
At the completion of this activity, participants should be better able to:
Discuss current and emerging data for the treatment of vitiligo and hyperpigmentation disorders.
Identify safe and effective treatment options for non-segmental vitiligo and melasma.
Translate safety and efficacy data on JAK Inhibitors for the management of alopecia areata (AA)
Describe strategies to individualize care when using new treatments for the management AA
Intended Audience
Faculty
Andrew Alexis, MD, MPH
Vice-Chair for Diversity and Inclusion, Dept. of Dermatology
Professor of Clinical Dermatology
Weill Cornell Medicine
New York, NY
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Natasha Mesinkovska, MD, PhD
Vice Chair, Clinical Research
University of California Irvine
Irvine, CA
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: BMS, LEO, Novartis, Almirall
Consultant: Leo, Galderma, Pfizer, Sanofi- Regeneron
Speakers’ Bureau or Honoraria: Regeneron, SANOFI-Genzyme, Pfizer, BMS
Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen
Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel
Advisory Board: Pfizer, Lilly, Concert, Abbvie, Galderma
Grant/Research Support: Pfizer
Consultant: National Alopecia Areata Foundation
Speakers’ Bureau or Honoraria: Lilly
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.